Cargando…
Unleashing the Therapeutic Potential of CAR-T Cell Therapy Using Gene-Editing Technologies
Chimeric antigen receptor (CAR) T-cell therapy, an emerging immunotherapy, has demonstrated promising clinical results in hematological malignancies including B-cell malignancies. However, accessibility to this transformative medicine is highly limited due to the complex process of manufacturing, li...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society for Molecular and Cellular Biology
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125425/ https://www.ncbi.nlm.nih.gov/pubmed/30110720 http://dx.doi.org/10.14348/molcells.2018.0242 |
_version_ | 1783353163748737024 |
---|---|
author | Jung, In-Young Lee, Jungmin |
author_facet | Jung, In-Young Lee, Jungmin |
author_sort | Jung, In-Young |
collection | PubMed |
description | Chimeric antigen receptor (CAR) T-cell therapy, an emerging immunotherapy, has demonstrated promising clinical results in hematological malignancies including B-cell malignancies. However, accessibility to this transformative medicine is highly limited due to the complex process of manufacturing, limited options for target antigens, and insufficient anti-tumor responses against solid tumors. Advances in gene-editing technologies, such as the development of Zinc Finger Nucleases (ZFNs), Transcription Activator-Like Effector Nucleases (TALENs), and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR/Cas9), have provided novel engineering strategies to address these limitations. Development of next-generation CAR-T cells using gene-editing technologies would enhance the therapeutic potential of CAR-T cell treatment for both hematologic and solid tumors. Here we summarize the unmet medical needs of current CAR-T cell therapies and gene-editing strategies to resolve these challenges as well as safety concerns of gene-edited CAR-T therapies. |
format | Online Article Text |
id | pubmed-6125425 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Korean Society for Molecular and Cellular Biology |
record_format | MEDLINE/PubMed |
spelling | pubmed-61254252018-09-10 Unleashing the Therapeutic Potential of CAR-T Cell Therapy Using Gene-Editing Technologies Jung, In-Young Lee, Jungmin Mol Cells Minireview Chimeric antigen receptor (CAR) T-cell therapy, an emerging immunotherapy, has demonstrated promising clinical results in hematological malignancies including B-cell malignancies. However, accessibility to this transformative medicine is highly limited due to the complex process of manufacturing, limited options for target antigens, and insufficient anti-tumor responses against solid tumors. Advances in gene-editing technologies, such as the development of Zinc Finger Nucleases (ZFNs), Transcription Activator-Like Effector Nucleases (TALENs), and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR/Cas9), have provided novel engineering strategies to address these limitations. Development of next-generation CAR-T cells using gene-editing technologies would enhance the therapeutic potential of CAR-T cell treatment for both hematologic and solid tumors. Here we summarize the unmet medical needs of current CAR-T cell therapies and gene-editing strategies to resolve these challenges as well as safety concerns of gene-edited CAR-T therapies. Korean Society for Molecular and Cellular Biology 2018-08-31 2018-08-14 /pmc/articles/PMC6125425/ /pubmed/30110720 http://dx.doi.org/10.14348/molcells.2018.0242 Text en © The Korean Society for Molecular and Cellular Biology. All rights reserved. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/. |
spellingShingle | Minireview Jung, In-Young Lee, Jungmin Unleashing the Therapeutic Potential of CAR-T Cell Therapy Using Gene-Editing Technologies |
title | Unleashing the Therapeutic Potential of CAR-T Cell Therapy Using Gene-Editing Technologies |
title_full | Unleashing the Therapeutic Potential of CAR-T Cell Therapy Using Gene-Editing Technologies |
title_fullStr | Unleashing the Therapeutic Potential of CAR-T Cell Therapy Using Gene-Editing Technologies |
title_full_unstemmed | Unleashing the Therapeutic Potential of CAR-T Cell Therapy Using Gene-Editing Technologies |
title_short | Unleashing the Therapeutic Potential of CAR-T Cell Therapy Using Gene-Editing Technologies |
title_sort | unleashing the therapeutic potential of car-t cell therapy using gene-editing technologies |
topic | Minireview |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125425/ https://www.ncbi.nlm.nih.gov/pubmed/30110720 http://dx.doi.org/10.14348/molcells.2018.0242 |
work_keys_str_mv | AT junginyoung unleashingthetherapeuticpotentialofcartcelltherapyusinggeneeditingtechnologies AT leejungmin unleashingthetherapeuticpotentialofcartcelltherapyusinggeneeditingtechnologies |